This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by D’Angelica, M. Articles by Saltz, L. B Search for Related Content PubMed PubMed Citation Articles by D’Angelica, M. Articles by Saltz, L. B

Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

¹ Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
² Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
³ Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA

Correspondence: Address correspondence and reprint requests to: Michael D’Angelica, MD; E-mail: dangelim{at}mskcc.org

Background: Bevacizumab (bev) is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). Perioperative bev is now commonly used in patients undergoing hepatic resection. Little is known, however, about the safety of perioperative bev use in the setting of hepatic resection.

Methods: Computerized pharmacy records were used to identify all patients who received bev between January 2004 and June 2005. Patients who underwent hepatectomy for colorectal metastases and received bev within 12 weeks of surgery were identified and compared with a group of matched historical controls.

Results: Thirty-two patients underwent hepatic resection of colorectal cancer metastases and received bev within the specified perioperative period. Sixteen patients received bev before surgery and 24 received bev after surgery. A subset of eight patients received bev both before and after surgery. The median time between bev administration and surgery was 6.9 weeks before (range, 3–15 weeks) and 7.4 weeks after (range, 5–15 weeks). Perioperative complications occurred in 13 patients (40.6%), two of which were considered major complications. There was no statistically significant difference in perioperative morbidity and severity of complications when compared with a set of matched controls.

Conclusions: Clinical experience thus far does not indicate a statistically significantly increased risk of perioperative complications with the incorporation of bev into pre- and/or postoperative treatment paradigms. Given the long half-life of bev and the potential for anti-VEGF therapy to impede wound healing and/or liver regeneration, we continue to favor a window of 6 to 8 weeks between bev administration and surgery.

Key Words: Colorectal metastases • Hepatectomy • Bevacizumab • Bev • Perioperative morbidity

This article has been cited by other articles:

				S. B. Kesmodel, L. M. Ellis, E. Lin, G. J. Chang, E. K. Abdalla, S. Kopetz, J.-N. Vauthey, M. A. Rodriguez-Bigas, S. A. Curley, and B. W. Feig Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases J. Clin. Oncol., November 10, 2008; 26(32): 5254 - 5260. [Abstract] [Full Text] [PDF]

				D. Zorzi, Y. S. Chun, D. C. Madoff, E. K. Abdalla, and J.-N. Vauthey Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases Ann. Surg. Oncol., October 1, 2008; 15(10): 2765 - 2772. [Abstract] [Full Text] [PDF]

				A. J. Bilchik and J. R. Hecht Perioperative Risks of Bevacizumab and Other Biologic Agents for Hepatectomy: Theoretical or Evidence Based? J. Clin. Oncol., April 10, 2008; 26(11): 1786 - 1788. [Full Text] [PDF]

				C. Brostjan, K. Gebhardt, B. Gruenberger, V. Steinrueck, H. Zommer, H. Freudenthaler, S. Roka, and T. Gruenberger Neoadjuvant Treatment of Colorectal Cancer with Bevacizumab: The Perioperative Angiogenic Balance Is Sensitive to Systemic Thrombospondin-1 Levels Clin. Cancer Res., April 1, 2008; 14(7): 2065 - 2074. [Abstract] [Full Text] [PDF]

				N. Kemeny Presurgical Chemotherapy in Patients Being Considered for Liver Resection Oncologist, July 1, 2007; 12(7): 825 - 839. [Abstract] [Full Text] [PDF]

				P.-A. Clavien, H. Petrowsky, M. L. DeOliveira, and R. Graf Strategies for Safer Liver Surgery and Partial Liver Transplantation N. Engl. J. Med., April 12, 2007; 356(15): 1545 - 1559. [Full Text] [PDF]